Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Avantika Barve (East Hanover, United States of America), Avantika Barve, Hanns-Christian Tillmann, Emma Ilsley, Janardhana Vemula, Alexandra Nica, Georges Imbert, Walid Elbast, Hilmar Schiller, Gian Camenisch, Ralph Woessner. Impact of co-administration of fevipiprant (QAW039) and SLCO1B1 genotype on the PK of simvastatin and rosuvastatin. Eur Respir J 2016; 48: Suppl. 60, 1108

Member's Comments

No comment yet.

Related content which might interest you: No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 Pharmacokinetic (PK) interaction of ketoconazole (KC), clarithromycin (CM) and midazolam (MZ) with riociguat Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Safety, tolerability, pharmacokinetics and pharmacodynamics after repeated once or twice daily RVT-1201, a TPH inhibitor for treatment of PAH Source: International Congress 2019 – Pulmonary hypertension: clinical Year: 2019 Pharmacokinetic (PK) interaction of fixed-dose combination (FDC) antiretrovirals (ARV) with riociguat (rio) Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Pharmacokinetics (PK) and pharmacodynamics (PD) of tetomilast in stable COPD subjects Source: Eur Respir J 2006; 28: Suppl. 50, 661s Year: 2006 Safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of GSK573719 inhalation powder in healthy subjects Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 Effect of CYP3A4 inhibitors verapamil and itraconazole on the pharmacokinetics of AZD7986, an oral DPP1 inhibitor Source: International Congress 2017 – Asthma management Year: 2017 Safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD7594 after single and multiple ascending inhaled doses in healthy Japanese males Source: International Congress 2017 – COPD management Year: 2017 The pharmacokinetics (PK) and pharmacodynamics (PD) of the fluticasone furoate (FF) and vilanterol (VI) combination in subjects with hepatic impairment Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012 Safety, immunogenicity and pharmacokinetics (PK) of a 120 mg/kg/week dose of alpha1-proteinase inhibitor in alpha1-antitrypsin deficiency Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 The effect of ketoconazole on the pharmacokinetics (PK) and pharmacodynamics (PD) of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in healthy subjects Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011 Safety, tolerability and pharmacokinetics (PK) of AZD8154 (a selective PI3K?d inhibitor) after single ascending inhaled doses in healthy volunteers Source: International Congress 2019 – Airway inflammation: pharmacological mechanisms and novel targets Year: 2019 Effect of moderate hepatic impairment (MHI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK) Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Differential effects of atorvastatin, pravastatin, rosuvastatin and simvastatin on lungs from mice exposed to cigarette smoke Source: Annual Congress 2012 - Cell culture and animal models of lung disease Year: 2012 The effects of multiple dosing of ketoconazole on the pharmacokinetics of a single dose ambrisentan Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008 Safety and pharmacokinetics of nintedanib plus sildenafil in the INSTAGE trial Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 Lack of effect of mild and moderate hepatic impairment or UGT1A1 genotype on the pharmacokinetics of inhaled indacaterol Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 The associations of polymorphism C3435T multidrug resistance gene (MDR1) and regimen of inhaled glucocorticosteroid therapy in bronchial asthma (BA) patients Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single (SD) and repeat (RD) inhaled doses of a novel phosphoinositide 3-kinase δ inhibitor (PI3Kδ), GSK2269557, administered to healthy smokers Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPD Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011